Literature DB >> 19630776

Role of regulatory T cells in tolerance to coagulation factors.

O Cao1, P A Loduca, R W Herzog.   

Abstract

The immune response to coagulation factors VIII or IX, in particular formation of inhibitory antibodies, complicates treatment of hemophilia. Therefore, a number of recent studies in animal models have explored novel approaches toward induction of immune tolerance in protein or gene replacement therapy. Strong evidence has emerged that regulatory T cells (Treg) are an important component of the mechanism by which tolerance is maintained and inhibitor formation, a T help dependent response, is prevented. Limited data in patients also support this concept. In particular, CD4+ CD25+ FoxP3+ Treg, whether naturally occurring or induced, have been invoked in suppression of antibody and of cytotoxic T lymphocyte responses to the therapeutic clotting factor. This review summarizes the data on this emerging concept of Treg-mediated regulation of the immune response in treatment of hemophilia, strategies and mechanisms of Treg induction and function, and the implications for development of immune tolerance protocols.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19630776      PMCID: PMC2911015          DOI: 10.1111/j.1538-7836.2009.03417.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  21 in total

1.  Generation of anergic and regulatory T cells following prolonged exposure to a harmless antigen.

Authors:  Tse-Ching Chen; Stephen P Cobbold; Paul J Fairchild; Herman Waldmann
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

2.  Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes".

Authors:  Anne S De Groot; Leonard Moise; Julie A McMurry; Erik Wambre; Laurence Van Overtvelt; Philippe Moingeon; David W Scott; William Martin
Journal:  Blood       Date:  2008-07-25       Impact factor: 22.113

3.  High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.

Authors:  Christina Hausl; Rafi U Ahmad; Maria Sasgary; Christopher B Doering; Pete Lollar; Günter Richter; Hans Peter Schwarz; Peter L Turecek; Birgit M Reipert
Journal:  Blood       Date:  2005-08-09       Impact factor: 22.113

4.  Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.

Authors:  Tie Chi Lei; David W Scott
Journal:  Blood       Date:  2005-03-15       Impact factor: 22.113

Review 5.  Gene therapy for treatment of inherited haematological disorders.

Authors:  Roland W Herzog; Ou Cao; J Nathan Hagstrom; Lixin Wang
Journal:  Expert Opin Biol Ther       Date:  2006-05       Impact factor: 4.388

6.  Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells.

Authors:  Eric Dobrzynski; Julie C Fitzgerald; Ou Cao; Federico Mingozzi; Lixin Wang; Roland W Herzog
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-10       Impact factor: 11.205

7.  Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer.

Authors:  Eric Dobrzynski; Federico Mingozzi; Yi-Lin Liu; Elisabeth Bendo; Ou Cao; Lixin Wang; Roland W Herzog
Journal:  Blood       Date:  2004-04-22       Impact factor: 22.113

8.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

Authors:  Federico Mingozzi; Yi-Lin Liu; Eric Dobrzynski; Antje Kaufhold; Jian Hua Liu; YuQin Wang; Valder R Arruda; Katherine A High; Roland W Herzog
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

9.  Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice.

Authors:  Baowei Peng; Peiqing Ye; Bruce R Blazar; Gordon J Freeman; David J Rawlings; Hans D Ochs; Carol H Miao
Journal:  Blood       Date:  2008-06-23       Impact factor: 22.113

10.  In vivo instruction of suppressor commitment in naive T cells.

Authors:  Irina Apostolou; Harald von Boehmer
Journal:  J Exp Med       Date:  2004-05-17       Impact factor: 14.307

View more
  21 in total

Review 1.  Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells.

Authors:  Carol H Miao
Journal:  Expert Rev Hematol       Date:  2010-08       Impact factor: 2.929

2.  Muscle-directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors.

Authors:  L Wang; J-P Louboutin; P Bell; J A Greig; Y Li; D Wu; J M Wilson
Journal:  J Thromb Haemost       Date:  2011-10       Impact factor: 5.824

3.  B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells.

Authors:  Jonathan Skupsky; Ai-Hong Zhang; Yan Su; David W Scott
Journal:  Mol Ther       Date:  2010-05-18       Impact factor: 11.454

4.  Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.

Authors:  Carol H Miao
Journal:  J Genet Syndr Gene Ther       Date:  2011-12-23

Review 5.  Liver induced transgene tolerance with AAV vectors.

Authors:  Geoffrey D Keeler; David M Markusic; Brad E Hoffman
Journal:  Cell Immunol       Date:  2017-12-05       Impact factor: 4.868

6.  Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells.

Authors:  Xiaomei Wang; Jin Su; Alexandra Sherman; Geoffrey L Rogers; Gongxian Liao; Brad E Hoffman; Kam W Leong; Cox Terhorst; Henry Daniell; Roland W Herzog
Journal:  Blood       Date:  2015-02-19       Impact factor: 22.113

7.  In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.

Authors:  Chao-Lien Liu; Peiqing Ye; Benjamin C Yen; Carol H Miao
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

8.  Induction of tolerance to factor VIII by transient co-administration with rapamycin.

Authors:  B Moghimi; B K Sack; S Nayak; D M Markusic; C S Mah; R W Herzog
Journal:  J Thromb Haemost       Date:  2011-08       Impact factor: 5.824

9.  Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.

Authors:  Moanaro Biswas; Geoffrey L Rogers; Alexandra Sherman; Barry J Byrne; David M Markusic; Haiyan Jiang; Roland W Herzog
Journal:  Thromb Haemost       Date:  2016-09-29       Impact factor: 5.249

10.  Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer.

Authors:  Roland W Herzog; Mario Cooper; George Q Perrin; Moanaro Biswas; Ashley T Martino; Laurence Morel; Cox Terhorst; Brad E Hoffman
Journal:  Cell Immunol       Date:  2017-08-01       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.